Biogen’s Aduhelm Sales Total $2 Million in the Second Quarter

Pharmaceutical manufacturer Biogen reported its on thursday Controversial Alzheimer’s drug aduhelm It brought in $2 million in its first few weeks, which is the first revenue for a treatment that is expected to generate billions of dollars in a few years and strain Medicare’s budget. The company did not disclose the number of patients who …